1,746
Participants
Start Date
September 30, 2024
Primary Completion Date
September 30, 2028
Study Completion Date
March 31, 2029
Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)
Therapy for early rhythm control will be either by use of approved antiarrhythmic drugs (e.g. amiodarone, dronedarone, flecainide, propafenone), approved approaches and devices for ablation, or electric cardio version.
Usual care for atrial fibrillation
Usual care for atrial fibrillation according to current guidelines. Usual care will mainly comprise rate control by approved drugs. We expect, that usual care will also comprise therapy for rhythm control in a small group of patients.
University Heart & Vascular Center Hamburg, Department of Cardiology
UNKNOWN
Department of Neurology, Royal Melbourne Hospital
UNKNOWN
Melbourne Heart Centre, Royal Melbourne Hospital
UNKNOWN
Hotchkiss Brain Institute, University of Calgary
OTHER
Department of Neurology and Neurosurgery, Brain Center, University Medical Center Utrecht
UNKNOWN
UMC Utrecht
OTHER
Edinburgh Clinical Trials Unit, Cerebrovascular Research Group, Centre for Clinical Brain Sciences, University of Edinburgh
UNKNOWN
Department of Cardiovascular Sciences, University of Leicester British Heart Foundation Cardiovascular Research Centre
UNKNOWN
Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf
UNKNOWN
CTC-NORTH
UNKNOWN
Stroke Alliance for Europe (SAFE)
UNKNOWN
Kompetenznetz Vorhofflimmern e.V. (AFNET)
UNKNOWN
Universitätsklinikum Hamburg-Eppendorf
OTHER